Zacks Investment Research upgraded shares of Imperva (NASDAQ:IMPV) from a hold rating to a strong-buy rating in a research note released on Friday, February 16th. They currently have $53.00 target price on the software maker’s stock.
According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “
Other analysts have also issued research reports about the company. KeyCorp reiterated a hold rating on shares of Imperva in a report on Tuesday, October 24th. ValuEngine upgraded Imperva from a sell rating to a hold rating in a report on Thursday, February 15th. Piper Jaffray Companies upgraded Imperva from a neutral rating to an overweight rating and set a $52.00 price objective for the company in a report on Friday, February 9th. Oppenheimer reissued a buy rating and issued a $55.00 target price on shares of Imperva in a research report on Thursday, November 9th. Finally, Evercore ISI reissued a buy rating and issued a $56.00 target price on shares of Imperva in a research report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Imperva has a consensus rating of Buy and an average target price of $53.14.
Imperva (NASDAQ:IMPV) traded down $0.35 during trading on Friday, reaching $46.50. The company’s stock had a trading volume of 689,318 shares, compared to its average volume of 423,184. The stock has a market capitalization of $1,619.40, a price-to-earnings ratio of 68.38 and a beta of 1.65. Imperva has a one year low of $37.17 and a one year high of $52.40.
Imperva (NASDAQ:IMPV) last posted its earnings results on Thursday, February 8th. The software maker reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.13. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.11 million. Imperva had a negative return on equity of 3.28% and a net margin of 7.11%. Imperva’s revenue was up 16.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.32 earnings per share. equities research analysts predict that Imperva will post -0.17 EPS for the current year.
In other news, Director Anthony J. Bettencourt sold 66,037 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $46.98, for a total transaction of $3,102,418.26. Following the sale, the director now directly owns 66,037 shares of the company’s stock, valued at approximately $3,102,418.26. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CRO Michael D. Mooney sold 24,454 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $47.18, for a total transaction of $1,153,739.72. Following the sale, the executive now directly owns 24,454 shares in the company, valued at $1,153,739.72. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Carillon Tower Advisers Inc. purchased a new position in Imperva in the 4th quarter valued at about $36,802,000. Alyeska Investment Group L.P. lifted its stake in Imperva by 89.3% in the 3rd quarter. Alyeska Investment Group L.P. now owns 907,615 shares of the software maker’s stock valued at $39,390,000 after buying an additional 428,163 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its stake in Imperva by 171.4% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 475,000 shares of the software maker’s stock valued at $20,702,000 after buying an additional 300,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Imperva by 55.2% in the 4th quarter. Renaissance Technologies LLC now owns 798,100 shares of the software maker’s stock valued at $31,685,000 after buying an additional 283,700 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in Imperva by 11.3% in the 2nd quarter. BlackRock Inc. now owns 2,124,043 shares of the software maker’s stock valued at $101,635,000 after buying an additional 215,170 shares in the last quarter.
WARNING: “Imperva (NASDAQ:IMPV) Rating Increased to Strong-Buy at Zacks Investment Research” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/03/12/imperva-impv-upgraded-by-zacks-investment-research-to-strong-buy.html.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.